DiaMedica prepares to end 10-month FDA hold on late-phase stroke trial by halving dose

DiaMedica prepares to end 10-month FDA hold on late-phase stroke trial by halving dose

Source: 
Fierce Biotech
snippet: 

DiaMedica Therapeutics thinks it has the data to get out from under a stubborn FDA clinical hold. Ten months after its phase 2/3 stroke clinical trial suffered the setback, the biotech is on the cusp of submitting evidence designed to explain the unexpected low blood pressure events and allay concerns.